Maastricht

• A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent/Metastatic Head … Recruiting
  2025-521917-24-00 5 2026-01-21 Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
• IMCISION: Towards organ preservation and cure via ultra-short immunotherapy in advanced oral cancer. The IMCISION II trial, an investigator … Recruiting
  2025-522500-24-00 5 2026-01-20 Head and Neck squamous cell carcinoma
• ​​Vorasidenib for the treatment of IDH-mutant astrocytoma after standard chemoradiotherapy Recruiting
  2024-519404-27-00 5 2026-01-16 ​​IDH-mutant grade 2 or 3 astrocytoma​
• A study to investigate the efficacy, safety, tolerability and pharmacokinetics of PKN605 in participants with atrial fibrillation Recruiting
  2025-520518-79-00 4 2026-01-06 Atrial Fibrillation
• Assessing the Efficacy of a Single Measurement and Adjustment Strategy for DOACs in Frail Older Patients. Recruiting
  2025-521362-10-00 11 2026-01-06 Frail older patients with atrial fibrillation or venous thromboembolis
• A Study to Learn About Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Infants Recruiting
  2022-503070-36-00 5 2025-12-23 Group B streptococcus (GBS) disease
• A study to evaluate the impact on metastases-free survival with the addition of saruparib vs placebo to a standard radiotherapy androgen dep … Recruiting
  2024-513586-39-00 5 2025-12-10 Prostate Cancer
• A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg … Recruiting
  2025-523083-21-00 5 2025-12-08 PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
• Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting
  2025-521382-27-00 10 2025-12-04 Moderately to Severely Active Crohn's Disease
• Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting
  2025-521381-10-00 5 2025-12-03 Moderately to Severely Active Ulcerative Colitis
• A Study to Learn About the Study Medicine Called PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants with Previously-treated Program … Recruiting
  2025-521281-97-00 5 2025-12-02 Non-Small Cell Lung Cancer (NSCLC)
• A Study of the Long-Term Safety and Efficacy of VX-670 in Patients With Myotonic Dystrophy Type I Recruiting
  2024-517983-47-00 9 2025-11-25 Myotonic Dystrophy
• Pasritamig vs Placebo in late line Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting
  2025-520927-26-00 5 2025-11-24 Metastatic Castration-resistant Prostate Cancer (mCRPC)
• A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advan … Recruiting
  2025-520566-22-00 5 2025-11-10 Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Ca
• A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants with PD-1 … Recruiting
  2023-506384-34-00 7 2025-11-05 Locally advanced or metastatic urothelial carcinoma
• TRITON-CM: A Study to Evaluate Nucresiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Recruiting
  2024-519917-72-00 5 2025-10-29 Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
• Increasing the dosing interval of osimertinib in patients with EGFR mutated locally advanced or meta-static non-small cell lung cancer - OSI … Recruiting
  2024-514693-47-01 11 2025-10-28 EGFR mutated locally advanced or metastatic non-small cell lung cancer
• EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure … Recruiting
  2025-521188-11-00 5 2025-10-15 Type 2 diabetes
• Clinical Randomised Phase 2 Trial of AP31969 versus Placebo for Rhythm Control of Atrial Fibrillation. Recruiting
  2025-521377-14-00 4 2025-10-06 Atrial fibrillation
• Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer Recruiting
  2024-514822-21-00 5 2025-10-02 Platinum-resistant Ovarian Cancer
• A phase 2 study of the effectiveness of golcadomide (CC-99282) for patients with large B-cell lymphoma in the brain Recruiting
  2024-517051-12-00 4 2025-09-16 Relapsed primary large B-cel lymphoma of the central nervous system
• Evaluation of efficacy and safety of GSK5764227 (alone and in combination) in participants with previously treated advanced unresectable or … Recruiting
  2025-520672-26-00 9 2025-09-16 Gastrointestinal Neoplasms
• REDO-JAK: Dose REDuction Of JAnus Kinase inhibitors in patients with inflammatory rheumatic diseases Recruiting
  2025-520757-36-00 6 2025-09-15 Rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis
• 18F-FDG versus 68Ga-FAPI-46 as PET tracer in ER-positive breast cancer - a pilot study Recruiting
  2023-508066-15-01 4 2025-09-01 Hormone-positive breast cancer

Showing 73–96 of 321 trials